Klyss Biotech, Inc
Biotechnology ResearchCalifornia, United States2-10 Employees
Klyss Biotech is currently focused on a promising monoclonal antibody to be used as a potential therapy against hematological malignancies, including incurable cancers, such as multiple myeloma and certain non-Hodgkin lymphomas. Our antibody, ch128.1, targets the transferrin receptor (TfR), also known as CD71, which is a vulnerable molecule expressed at high levels on the surface of cancer cells. This antibody confers significant protection, including long-term survivors showing no sign of tumor, at a single low dose in a mouse xenograft model of disseminated human multiple myeloma. More recently, this antibody also was seen to confer protection in a particularly aggressive model of human non-Hodgkin lymphoma in a mouse xenograft model. Importantly, ch128.1 is non-neutralizing, meaning that the natural TfR ligands [both transferrin and hemochromatosis protein (HFE)], would not inhibit the binding of TfR by ch128.1, facilitating tumor targeting and decreasing the probability of unfavorable side effects. These properties and results indicate that ch128.1 is a promising therapeutic against human hematological malignancies.
1-888-653-2347 
support@leadiq.com 
